George Coukos

List of Publications by Year in descending order

311 papers	44,284 citations	3933 88 h-index	2385 198 g-index
335 all docs	335 docs citations	335 times ranked	50220 citing authors

#	Article	IF	Citations
1	Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discovery, 2022, 12, 108-133.	9.4	165
2	Identification of tumor antigens with immunopeptidomics. Nature Biotechnology, 2022, 40, 175-188.	17.5	93
3	Sensitive identification of neoantigens and cognate TCRs in human solid tumors. Nature Biotechnology, 2022, 40, 656-660.	17.5	41
4	High-Throughput Single-Cell TCRâ€“pMHC Dissociation Rate Measurements Performed by an Autonomous Microfluidic Cellular Processing Unit. ACS Sensors, 2022, 7, 159-165.	7.8	1
5	Lighting up the tumor fire with low-dose irradiation. Trends in Immunology, 2022, 43, 173-179.	6.8	26
6	A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors. Scientific Reports, 2022, 12, 1136.	3.3	2
7	A roadmap for driving CAR TÂcells toward the oncogenic immunopeptidome. Cancer Cell, 2022, 40, 20-22.	16.8	7
8	Deciphering the landscape of phosphorylated HLA-II ligands. IScience, 2022, 25, 104215.	4.1	3
9	Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. Lancet Oncology, The, 2022, 23, e157.	10.7	2
10	TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.. BioImpacts, 2022, 12, 65-86.	1.5	1
11	Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37, 1773-1811.	5.2	1
12	Low-dose irradiation for reversing immunotherapy resistance: how to translate?. , 2022, 10, e004939.		8
13	Cell therapies in ovarian cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110083.	3.2	20
14	Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction. Molecular and Cellular Proteomics, 2021, 20, 100080.	3.8	49
15	Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting. Cell Reports Medicine, 2021, 2, 100194.	6.5	77
16	Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer. Science Advances, 2021, 7, .	10.3	157
17	Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 2205-2227.	6.4	9
18	Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. Npj Vaccines, 2021, 6, 36.	6.0	27

#	Article	IF	Citations
19	Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab. Clinical and Translational Radiation Oncology, 2021, 27, 85-88.	1.7	8
20	Unsupervised Analysis of Flow Cytometry Data in a Clinical Setting Captures Cell Diversity and Allows Population Discovery. Frontiers in Immunology, 2021, 12, 633910.	4.8	8
21	Interpretation of T cell states from single-cell transcriptomics data using reference atlases. Nature Communications, 2021, 12, 2965.	12.8	210
22	In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.. Journal of Clinical Oncology, 2021, 39, 2533-2533.	1.6	0
23	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. Cell Reports, 2021, 36, 109412.	6.4	60
24	VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding. , 2021, 9, e002151.		16
25	Imaging angiogenesis in atherosclerosis in large arteries with 68Ga-NODAGA-RGD PET/CT: relationship with clinical atherosclerotic cardiovascular disease. EJNMMI Research, 2021, 11, 71.	2.5	12
26	Soluble trivalent engagers redirect cytolytic TÂcell activity toward tumor endothelial marker 1. Cell Reports Medicine, 2021, 2, 100362.	6.5	9
27	Microfluidic Device for Droplet Pairing by Combining Droplet Railing and Floating Trap Arrays. Micromachines, 2021, 12, 1076.	2.9	5
28	Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Model. Pharmaceutics, 2021, 13, 96.	4.5	8
29	Biological evaluation of new TEM1 targeting recombinant antibodies for radioimmunotherapy: In vitro, in vivo and in silico studies. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 158, 233-244.	4.3	3
30	Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. Journal of Experimental Medicine, 2021, 218, .	8.5	74
31	Myeloid antigen-presenting cell niches sustain antitumor TÂcells and license PD-1 blockade via CD28 costimulation. Cancer Cell, 2021, 39, 1623-1642.e20.	16.8	64
32	Reversion analysis reveals the in vivo immunogenicity of a poorly MHC I-binding cancer neoepitope. Nature Communications, 2021, 12, 6423.	12.8	18
33	High-throughput identification of human antigen-specific CD8+ and CD4+ T cells using soluble pMHC multimers. Methods in Enzymology, 2020, 631, 21-42.	1.0	3
34	miR-155 Overexpression in OT-1 CD8+ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen. Molecular Therapy - Oncolytics, 2020, 16, 111-123.	4.4	15
35	Neutrophils suppress tumorâ€infiltrating T cells in colon cancer via matrix metalloproteinaseâ€mediated activation of <scp>TGF</scp> Î². EMBO Molecular Medicine, 2020, 12, e10681.	6.9	100
36	Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment. Cytotherapy, 2020, 22, 780-791.	0.7	9

#	Article	IF	Citations
37	T-cell repertoire analysis and metrics of diversity and clonality. Current Opinion in Biotechnology, 2020, 65, 284-295.	6.6	79
38	Mineral and Amino Acid Profiling of Different Hematopoietic Populations from the Mouse Bone Marrow. International Journal of Molecular Sciences, 2020, 21, 6444.	4.1	4
39	High versus low dose irradiation for tumor immune reprogramming. Current Opinion in Biotechnology, 2020, 65, 268-283.	6.6	13
40	Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. Nature Immunology, 2020, 21, 1540-1551.	14.5	252
41	Structural dissimilarity from self drives neoepitope escape from immune tolerance. Nature Chemical Biology, 2020, 16, 1269-1276.	8.0	53
42	Guillain-BarrÃ© syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes. , 2020, 8, e001155.		3
43	Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference. Frontiers in Immunology, 2020, 11, 1981.	4.8	9
44	Turning up the heat on non-immunoreactive tumours: opportunities for clinical development. Lancet Oncology, The, 2020, 21, e419-e430.	10.7	128
45	Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. , 2020, 8, e000875.		16
46	Immune Therapy Opportunities in Ovarian Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e228-e240.	3.8	25
47	Multielemental Analysis of Low-Volume Samples Reveals Cancer-Specific Profile in Serum and Sorted Immune Cells. Analytical Chemistry, 2020, 92, 8750-8758.	6.5	7
48	High-throughput automated organoid culture via stem-cell aggregation in microcavity arrays. Nature Biomedical Engineering, 2020, 4, 863-874.	22.5	231
49	Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nature Communications, 2020, 11, 1293.	12.8	196
50	Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal. Frontiers in Immunology, 2020, 11, 1215.	4.8	32
51	Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure. Frontiers in Immunology, 2020, 11, 1350.	4.8	13
52	Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer. European Journal of Cancer, 2020, 135, 173-182.	2.8	32
53	Mass Spectrometry Based Immunopeptidomics Leads to Robust Predictions of Phosphorylated HLA Class I Ligands. Molecular and Cellular Proteomics, 2020, 19, 390-404.	3.8	47
54	All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy. Current Opinion in Biotechnology, 2020, 65, 75-87.	6.6	33

#	Article	IF	Citations
55	Biotechnologies to tackle the challenge of neoantigen identification. Current Opinion in Biotechnology, 2020, 65, 52-59.	6.6	25
56	Preclinical Evaluation and Dosimetry of [111In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1). Molecular Imaging and Biology, 2020, 22, 979-991.	2.6	15
57	Neoadjuvant immune-checkpoint blockade in resectable colon cancer. Nature Medicine, 2020, 26, 473-474.	30.7	12
58	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
59	Cathepsin S Regulates Antigen Processing and T Cell Activity in Non-Hodgkin Lymphoma. Cancer Cell, 2020, 37, 674-689.e12.	16.8	55
60	A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. Nature Biotechnology, 2020, 38, 426-432.	17.5	100
61	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis.. Journal of Clinical Oncology, 2020, 38, e15095-e15095.	1.6	3
62	Immunotherapy in Ovarian Cancer: Are We There Yet?. Journal of Clinical Oncology, 2019, 37, 2460-2471.	1.6	73
63	Rational combinations of immunotherapy with radiotherapy in ovarian cancer. Lancet Oncology, The, 2019, 20, e417-e433.	10.7	89
64	Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes. Nature Biotechnology, 2019, 37, 1283-1286.	17.5	208
65	Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells. , 2019, 7, 257.		120
66	CD8 Binding of MHC-Peptide Complexes in cis or trans Regulates CD8+ T-cell Responses. Journal of Molecular Biology, 2019, 431, 4941-4958.	4.2	7
67	Analysis of Secondary Structure Biases in Naturally Presented HLA-I Ligands. Frontiers in Immunology, 2019, 10, 2731.	4.8	8
68	A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinomaâ€"A Proof of Antigen Discovery Feasibility in Three Patients. Frontiers in Immunology, 2019, 10, 1832.	4.8	73
69	Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice. EJNMMI Research, 2019, 9, 53.	2.5	17
70	Integrating SpyCatcher/SpyTag covalent fusion technology into phage display workflows for rapid antibody discovery. Scientific Reports, 2019, 9, 12815.	3.3	15
71	Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals of Oncology, 2019, 30, 1902-1913.	1.2	144
72	Tumour-reactive T cell subsets in the microenvironment of ovarian cancer. British Journal of Cancer, 2019, 120, 424-434.	6.4	44

#	Article	IF	Citations
73	18F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1859-1868.	6.4	62
74	Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell, 2019, 35, 885-900.e10.	16.8	475
75	Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. Frontiers in Immunology, 2019, 10, 925.	4.8	288
76	High-throughput Screening of Human Tumor Antigenâ€“specific CD4 T Cells, Including Neoantigen-reactive T Cells. Clinical Cancer Research, 2019, 25, 4320-4331.	7.0	15
77	The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. , 2019, 7, 109.		129
78	Deep Response to Anti-PD-1 Therapy of Metastatic Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor With CD274/PD-L1 Amplification. JCO Precision Oncology, 2019, 3, 1-6.	3.0	10
79	Tumor Landscapes: Î²-Catenin Drives Immune Desertification. Clinical Cancer Research, 2019, 25, 2943-2945.	7.0	9
80	The NAD-Booster Nicotinamide Riboside Potently Stimulates Hematopoiesis through Increased Mitochondrial Clearance. Cell Stem Cell, 2019, 24, 405-418.e7.	11.1	143
81	Going Beyond the Sequences: TCR Binding Patterns at the Service of Cancer Detection. Cancer Research, 2019, 79, 1299-1301.	0.9	4
82	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309.		112
83	Microfluidic device performing on flow study of serial cellâ€“cell interactions of two cell populations. RSC Advances, 2019, 9, 41066-41073.	3.6	6
84	A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. Journal of Translational Medicine, 2019, 17, 391.	4.4	42
85	Measurement of Mitochondrial Mass and Membrane Potential in Hematopoietic Stem Cells and T-cells by Flow Cytometry. Journal of Visualized Experiments, 2019, , .	0.3	4
86	Safety and Tolerability of Adoptive Cell Therapy in Cancer. Drug Safety, 2019, 42, 315-334.	3.2	57
87	50-Gy Stereotactic Body Radiation Therapy to the Dominant Intraprostatic Nodule: Results From a Phase 1a/b Trial. International Journal of Radiation Oncology Biology Physics, 2019, 103, 320-334.	0.8	28
88	Mass spectrometryâ€“driven exploration reveals nuances of neoepitope-driven tumor rejection. JCI Insight, 2019, 4, .	5.0	42
89	Predictive biomarkers for response to nivolumab in head and neck squamous cell carcinoma (HNSCC) (NCT#03652142).. Journal of Clinical Oncology, 2019, 37, 6060-6060.	1.6	1
90	T cellâ€“induced CSF1 promotes melanoma resistance to PD1 blockade. Science Translational Medicine, 2018, 10, .	12.4	229

#	Article	IF	Citations
91	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Science Translational Medicine, 2018, 10, .	12.4	326
92	High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound InterferonÎ³-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome. Molecular and Cellular Proteomics, 2018, 17, 533-548.	3.8	224
93	The C-terminal extension landscape of naturally presented HLA-I ligands. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 5083-5088.	7.1	48
94	Sensitive and frequent identification of high avidity neo-epitopeÂspecific CD8 + T cells in immunotherapy-naive ovarian cancer. Nature Communications, 2018, 9, 1092.	12.8	122
95	The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands. Journal of Immunology, 2018, 201, 3705-3716.	0.8	145
96	A severe case of refractory esophageal stenosis induced by nivolumab and responding to tocilizumab therapy. , 2018, 6, 156.		58
97	Two-Dimensional Label-Free Affinity Analysis of Tumor-Specific CD8 T Cells with a Biomimetic Plasmonic Sensor. ACS Sensors, 2018, 3, 2286-2295.	7.8	24
98	A severe case of neuro-SjÃ¶grenâ€™s syndrome induced by pembrolizumab. , 2018, 6, 110.		40
99	Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome*. Molecular and Cellular Proteomics, 2018, 17, 2347-2357.	3.8	105
100	Labelâ€Free Optofluidic Nanobiosensor Enables Realâ€Time Analysis of Singleâ€Cell Cytokine Secretion. Small, 2018, 14, e1800698.	10.0	70
101	Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis, 2018, 21, 425-532.	7.2	429
102	Current Opinion and Knowledge on Peritoneal Carcinomatosis: A Survey among a Swiss Oncology Network. Chemotherapy, 2018, 63, 143-147.	1.6	5
103	Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 2017, 17, 254-268.	28.4	527
104	Label-free identification of activated T lymphocytes through tridimensional microsensors on chip. Biosensors and Bioelectronics, 2017, 94, 193-199.	10.1	36
105	In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cellâ€“recognized tumor antigen T-cell epitopes. Journal of Biological Chemistry, 2017, 292, 11840-11849.	3.4	28
106	Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. OncoImmunology, 2017, 6, e1326442.	4.6	48
107	TIE-2 expressing monocytes in human cancers. OncoImmunology, 2017, 6, e1303585.	4.6	42
108	Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis. Nature Communications, 2017, 8, 593.	12.8	175

#	Article	IF	Citations
109	Radiotherapy combination opportunities leveraging immunity for the next oncology practice. Ca-A Cancer Journal for Clinicians, 2017, 67, 65-85.	329.8	344
110	Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy. Clinical Cancer Research, 2017, 23, 1955-1966.	7.0	27
111	The ovarian cancer oncobiome. Oncotarget, 2017, 8, 36225-36245.	1.8	129
112	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Donâ€™t Forget the Fuel. Frontiers in Immunology, 2017, 8, 267.	4.8	61
113	â€˜Hotspotsâ€™ of Antigen Presentation Revealed by Human Leukocyte Antigen Ligandomics for Neoantigen Prioritization. Frontiers in Immunology, 2017, 8, 1367.	4.8	133
114	Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity. PLoS Computational Biology, 2017, 13, e1005725.	3.2	250
115	Phage antibody display libraries: a powerful antibody discovery platform for immunotherapy. Critical Reviews in Biotechnology, 2016, 36, 276-289.	9.0	88
116	Neoantigen-based cancer immunotherapy. Annals of Translational Medicine, 2016, 4, 262-262.	1.7	63
117	Combine and Conquer: Double CTLA-4 and PD-1 Blockade Combined with Whole Tumor Antigen Vaccine Cooperate to Eradicate Tumors. Cancer Research, 2016, 76, 6765-6767.	0.9	7
118	Human melanomas and ovarian cancers overexpressing mechanical barrier molecule genes lack immune signatures and have increased patient mortality risk. OncoImmunology, 2016, 5, e1240857.	4.6	56
119	Mass spectrometry-based antigen discovery for cancer immunotherapy. Current Opinion in Immunology, 2016, 41, 9-17.	5.5	165
120	1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2). Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4330-4333.	2.2	35
121	The Human Vaccines Project: A roadmap for cancer vaccine development. Science Translational Medicine, 2016, 8, 334ps9.	12.4	162
122	Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy. OncoImmunology, 2016, 5, e1062210.	4.6	4
123	TCR-engineered T cells to treat tumors: Seeing but not touching?. Seminars in Immunology, 2016, 28, 10-21.	5.6	62
124	TIE-2-expressing monocytes are lymphangiogenic and associate specifically with lymphatics of human breast cancer. OncoImmunology, 2016, 5, e1073882.	4.6	37
125	Personalized approaches to active immunotherapy in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2016, 1865, 72-82.	7.4	41
126	EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).. Journal of Clinical Oncology, 2016, 34, TPS8571-TPS8571.	1.6	7

#	Article	IF	Citations
127	Whole Tumor Antigen Vaccines: Where Are We?. Vaccines, 2015, 3, 344-372.	4.4	203
128	Overexpression ofGPC6andTMEM132Din Early Stage Ovarian Cancer Correlates with CD8+ T-Lymphocyte Infiltration and Increased Patient Survival. BioMed Research International, 2015, 2015, 1-9.	1.9	20
129	Targeting the tumor vasculature to enhance T cell activity. Current Opinion in Immunology, 2015, 33, 55-63.	5.5	237
130	Potential approaches for more successful dendritic cell-based immunotherapy. Expert Opinion on Biological Therapy, 2015, 15, 569-582.	3.1	30
131	Angiogenic Activity of Breast Cancer Patientsâ€™ Monocytes Reverted by Combined Use of Systems Modeling and Experimental Approaches. PLoS Computational Biology, 2015, 11, e1004050.	3.2	18
132	Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells. Journal of Nanobiotechnology, 2015, 13, 26.	9.1	63
133	The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28â€“Costimulated T Cells Prepared for Adoptive Therapy. Clinical Cancer Research, 2015, 21, 2840-2850.	7.0	52
134	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: A Biomarker for Use Beyond Prognosis?. Journal of Clinical Oncology, 2015, 33, 1297-1298.	1.6	9
135	Targeting Programmed Cell Death 1 in Ovarian Cancer. Journal of Clinical Oncology, 2015, 33, 3987-3989.	1.6	18
136	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	28.4	839
137	Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers. Cancer Cell, 2015, 28, 529-540.	16.8	601
138	High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools. OncoImmunology, 2015, 4, e1029702.	4.6	17
139	T Cells Bearing a Chimeric Antigen Receptor against Prostate-Specific Membrane Antigen Mediate Vascular Disruption and Result in Tumor Regression. Cancer Immunology Research, 2015, 3, 68-84.	3.4	84
140	CEA-targeted engineered IL2: Clinical confirmation of tumor targeting and evidence of intra-tumoral immune activation.. Journal of Clinical Oncology, 2015, 33, 3016-3016.	1.6	12
141	Autologous oxidized whole-tumor antigen vaccine in combination with angiogenesis blockade to elicit antitumor immune response in ovarian cancer.. Journal of Clinical Oncology, 2015, 33, 5519-5519.	1.6	0
142	Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model. Cancer Biology and Therapy, 2014, 15, 443-451.	3.4	20
143	Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumorsâ€”Response. Cancer Research, 2014, 74, 633-634.	0.9	44
144	Bone marrow-derived cells are implicated as a source of lymphatic endothelial progenitors in human breast cancer. OncoImmunology, 2014, 3, e29080.	4.6	23

#	Article	IF	Citations
145	T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy. Cancer Discovery, 2014, 4, 522-526.	9.4	357
146	Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nature Medicine, 2014, 20, 607-615.	30.7	742
147	CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor. Clinical Cancer Research, 2014, 20, 44-55.	7.0	241
148	Successful engineering cancer immunotherapy. European Journal of Immunology, 2014, 44, 318-320.	2.9	2
149	Development of 124I Immuno-PET Targeting Tumor Vascular TEM1/Endosialin. Journal of Nuclear Medicine, 2014, 55, 500-507.	5.0	28
150	Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer. International Journal of Biochemistry and Cell Biology, 2014, 53, 389-398.	2.8	15
151	Tumor endothelial marker 1â€“specific DNA vaccination targets tumor vasculature. Journal of Clinical Investigation, 2014, 124, 1497-1511.	8.2	59
152	Shikonin-loaded antibody-armed nanoparticles for targeted therapy of ovarian cancer. International Journal of Nanomedicine, 2014, 9, 1855.	6.7	48
153	Immuno-imaging and -therapy in ovarian cancer and sarcoma with de novo single-chain fv-fc fusion protein targeting TEM1/CD248. , 2014, 2, .		0
154	Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. Oncotarget, 2014, 5, 6994-7012.	1.8	14
155	What Is the Future of Immunotherapy in Ovarian Cancer?. , 2014, , 323-337.		0
156	Angiogenesis and Immune Suppression in Cancer. , 2014, , 213-238.		0
157	A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. Journal of Translational Medicine, 2013, 11, 149.	4.4	57
158	Deciphering and Reversing Tumor Immune Suppression. Immunity, 2013, 39, 61-73.	14.3	496
159	Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors. Cancer Research, 2013, 73, 3591-3603.	0.9	604
160	A New Twist on Radiation Oncology: Low-Dose Irradiation Elicits Immunostimulatory Macrophages that Unlock Barriers to Tumor Immunotherapy. Cancer Cell, 2013, 24, 559-561.	16.8	36
161	A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. Clinical Cancer Research, 2013, 19, 4801-4815.	7.0	178
162	Specific targeting of cancer cells by multifunctional mitoxantrone-conjugated magnetic nanoparticles. Journal of Drug Targeting, 2013, 21, 328-340.	4.4	55

#	Article	IF	Citations
163	Tamoxifen loaded folic acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer. Colloids and Surfaces B: Biointerfaces, 2013, 106, 117-125.	5.0	91
164	Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the bloodâ€“brain barrier divide. Expert Opinion on Drug Delivery, 2013, 10, 907-926.	5.0	92
165	TIE2-expressing monocytes: A novel cellular biomarker for hepatocellular carcinoma?. Hepatology, 2013, 57, 1294-1296.	7.3	10
166	Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. OncoImmunology, 2013, 2, e22664.	4.6	154
167	Replenish the source within. OncoImmunology, 2013, 2, e25912.	4.6	8
168	Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study. Cancer Immunology Research, 2013, 1, 168-178.	3.4	43
169	Therapeutic PD-1 Pathway Blockade Augments with Other Modalities of Immunotherapy T-Cell Function to Prevent Immune Decline in Ovarian Cancer. Cancer Research, 2013, 73, 6900-6912.	0.9	253
170	TIE-2 and VEGFR Kinase Activities Drive Immunosuppressive Function of TIE-2â€“Expressing Monocytes in Human Breast Tumors. Clinical Cancer Research, 2013, 19, 3439-3449.	7.0	32
171	Predicting time to ovarian carcinoma recurrence using protein markers. Journal of Clinical Investigation, 2013, 123, 3740-50.	8.2	46
172	Targeting Cytokines: Production and Characterization of Anti-TNF-Î± scFvs by Phage Display Technology. Current Pharmaceutical Design, 2013, 19, 2839-2847.	1.9	21
173	A Combined Array-Based Comparative Genomic Hybridization and Functional Library Screening Approach Identifies mir-30d As an Oncomir in Cancer. Cancer Research, 2012, 72, 154-164.	0.9	53
174	Redirected Antitumor Activity of Primary Human Lymphocytes Transduced With a Fully Human Anti-mesothelin Chimeric Receptor. Molecular Therapy, 2012, 20, 633-643.	8.2	161
175	Know thy enemy. OncoImmunology, 2012, 1, 575-577.	4.6	18
176	Genetic and Pharmacologic Inhibition of Complement Impairs Endothelial Cell Function and Ablates Ovarian Cancer Neovascularization. Neoplasia, 2012, 14, 994-IN1.	5.3	103
177	A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. Journal of Translational Medicine, 2012, 10, 157.	4.4	95
178	A Xenograft Mouse Model Coupled with In-depth Plasma Proteome Analysis Facilitates Identification of Novel Serum Biomarkers for Human Ovarian Cancer. Journal of Proteome Research, 2012, 11, 678-691.	3.7	51
179	Primary Human Ovarian Epithelial Cancer Cells Broadly Express HER2 at Immunologically-Detectable Levels. PLoS ONE, 2012, 7, e49829.	2.5	60
180	T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis. Cancer Research, 2012, 72, 2162-2171.	0.9	663

#	Article	IF	Citations
181	Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology, Immunotherapy, 2012, 61, 629-641.	4.2	109
182	Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis. Gynecologic Oncology, 2012, 124, 192-198.	1.4	527
183	High-Throughput Biomarker Segmentation on Ovarian Cancer Tissue Microarrays via Hierarchical Normalized Cuts. IEEE Transactions on Biomedical Engineering, 2012, 59, 1240-1252.	4.2	29
184	miRNAs in Human Cancer. Methods in Molecular Biology, 2012, 822, 295-306.	0.9	56
185	A phase I, dose escalation trial to assess the safety and biological activity of recombinant human interleukin-18 (SB-485232) in combination with pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer.. Journal of Clinical Oncology, 2012, 30, 5065-5065.	1.6	4
186	Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature, 2011, 475, 226-230.	27.8	1,071
187	Cancer immunotherapy comes of age. Nature, 2011, 480, 480-489.	27.8	3,115
188	Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines. International Reviews of Immunology, 2011, 30, 150-182.	3.3	91
189	Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses. PLoS ONE, 2011, 6, e28732.	2.5	43
190	Integrated Analysis of Multiple Microarray Datasets Identifies a Reproducible Survival Predictor in Ovarian Cancer. PLoS ONE, 2011, 6, e18202.	2.5	35
191	Tumor vascular biomarkers: New opportunities for cancer diagnostics1. Cancer Biomarkers, 2011, 8, 253-271.	1.7	14
192	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	28.4	1,084
193	The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nature Reviews Immunology, 2011, 11, 702-711.	22.7	390
194	Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform. Journal of Immunological Methods, 2011, 363, 221-232.	1.4	44
195	Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecologic Oncology, 2011, 120, 464-469.	1.4	40
196	Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. Journal of Translational Medicine, 2011, 9, 198.	4.4	43
197	Tumor immune surveillance and ovarian cancer. Cancer and Metastasis Reviews, 2011, 30, 141-151.	5.9	47
198	Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. Journal of Translational Medicine, 2011, 9, 131.	4.4	52

#	Article	IF	Citations
199	Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. Journal of Translational Medicine, 2011, 9, 77.	4.4	38
200	Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes and Cancer, 2011, 50, 606-618.	2.8	90
201	Immunotherapy for Ovarian Cancer: What's Next?. Journal of Clinical Oncology, 2011, 29, 925-933.	1.6	116
202	In VivoPersistence, Tumor Localization, and Antitumor Activity of CAR-Engineered T Cells Is Enhanced by Costimulatory Signaling through CD137 (4-1BB). Cancer Research, 2011, 71, 4617-4627.	0.9	256
203	Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biology and Therapy, 2011, 12, 169-180.	3.4	33
204	Tissue-based immune monitoring II. Cancer Biology and Therapy, 2011, 12, 367-377.	3.4	21
205	Tissue-based immune monitoring I. Cancer Biology and Therapy, 2011, 12, 357-366.	3.4	10
206	MicroRNAs in Epithelial Ovarian Cancer. , 2011, , 309-342.		2
207	The Microenvironment of Ovarian Cancer: Lessons on Immune Mediated Tumor Rejection or Tolerance. , 2011, , 211-228.		1
208	The emergence of immunomodulation: Combinatorial immunochemotherapy opportunities for the next decade. Gynecologic Oncology, 2010, 116, 222-233.	1.4	33
209	Identification of MicroRNAs Regulating Reprogramming Factor LIN28 in Embryonic Stem Cells and Cancer Cells. Journal of Biological Chemistry, 2010, 285, 41961-41971.	3.4	136
210	Double-Negative Feedback Loop between Reprogramming Factor LIN28 and microRNA let-7 Regulates Aldehyde Dehydrogenase 1â€“Positive Cancer Stem Cells. Cancer Research, 2010, 70, 9463-9472.	0.9	150
211	Whole tumor antigen vaccines. Seminars in Immunology, 2010, 22, 132-143.	5.6	201
212	Angiogenesis and the Tumor Vasculature as Antitumor Immune Modulators: The Role of Vascular Endothelial Growth Factor and Endothelin. Current Topics in Microbiology and Immunology, 2010, 344, 129-148.	1.1	76
213	Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers. PLoS ONE, 2010, 5, e10277.	2.5	362
214	Expression of Activated PIK3CA in Ovarian Surface Epithelium Results in Hyperplasia but Not Tumor Formation. PLoS ONE, 2009, 4, e4295.	2.5	30
215	Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Frontiers in Bioscience - Landmark, 2009, Volume, 1761.	3.0	59
216	Beyond CA125: the coming of age of ovarian cancer biomarkers. Biomarkers in Medicine, 2009, 3, 275-288.	1.4	44

#	Article	IF	Citations
217	Expression profile of microRNA in epithelial cancer: diagnosis, classification and prediction. Expert Opinion on Medical Diagnostics, 2009, 3, 25-36.	1.6	4
218	Endothelin B Receptor, a New Target in Cancer Immune Therapy. Clinical Cancer Research, 2009, 15, 4521-4528.	7.0	99
219	Intraepithelial T cells and tumor proliferation. Cancer, 2009, 115, 2891-2902.	4.1	118
220	In Vivo Dendritic Cell Tracking Using Fluorescence Lifetime Imaging and Near-Infrared-Emissive Polymersomes. Molecular Imaging and Biology, 2009, 11, 167-177.	2.6	43
221	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology, 2009, 22, 393-402.	5.5	241
222	KLF17 is a negative regulator of epithelialâ€“mesenchymal transition and metastasis in breast cancer. Nature Cell Biology, 2009, 11, 1297-1304.	10.3	172
223	Therapeutic MicroRNA Strategies in Human Cancer. AAPS Journal, 2009, 11, 747-57.	4.4	153
224	Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. Journal of Translational Medicine, 2009, 7, 104.	4.4	32
225	Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. Journal of Translational Medicine, 2009, 7, 49.	4.4	56
226	Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood, 2009, 114, 1141-1149.	1.4	688
227	Dendritic Cells: From Inducers of Specific T-Cell Responses to Promoters of Angiogenesis. , 2009, , 231-241.		1
228	Hierarchical Normalized Cuts: Unsupervised Segmentation of Vascular Biomarkers from Ovarian Cancer Tissue Microarrays. Lecture Notes in Computer Science, 2009, 12, 230-238.	1.3	11
229	MicroRNA epigenetic alterations in human cancer: One step forward in diagnosis and treatment. International Journal of Cancer, 2008, 122, 963-968.	5.1	84
230	Varying Coefficient Model with Unknown Withinâ€Subject Covariance for Analysis of Tumor Growth Curves. Biometrics, 2008, 64, 1023-1031.	1.4	14
231	The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature Cell Biology, 2008, 10, 202-210.	10.3	924
232	Modulation of the antitumor immune response by complement. Nature Immunology, 2008, 9, 1225-1235.	14.5	612
233	Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nature Medicine, 2008, 14, 28-36.	30.7	481
234	Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. Journal of Translational Medicine, 2008, 6, 2.	4.4	19

#	Article	IF	Citations
235	Whole tumor antigen vaccination using dendritic cells: Comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. Journal of Translational Medicine, 2008, 6, 21.	4.4	65
236	A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". Journal of Translational Medicine, 2008, 6, 81.	4.4	45
237	Mechanisms of microRNA deregulation in human cancer. Cell Cycle, 2008, 7, 2643-2646.	2.6	293
238	Biological Therapy with Oncolytic Herpesvirus. , 2008, 622, 221-233.		7
239	Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biology and Therapy, 2008, 7, 1194-1205.	3.4	69
240	Ultraconserved elements: Genomics, function and disease. RNA Biology, 2008, 5, 132-134.	3.1	43
241	MicroRNA Microarray Identifies Let-7i as a Novel Biomarker and Therapeutic Target in Human Epithelial Ovarian Cancer. Cancer Research, 2008, 68, 10307-10314.	0.9	343
242	miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biology and Therapy, 2008, 7, 255-264.	3.4	324
243	Ovarian Cancer Early Detection Claims Are Biased. Clinical Cancer Research, 2008, 14, 7574.1-7574.	7.0	37
244	Immunotherapy opportunities in ovarian cancer. Expert Review of Anticancer Therapy, 2008, 8, 243-257.	2.4	57
245	Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 7004-7009.	7.1	491
246	Distinct Effects of IL-18 on the Engraftment and Function of Human Effector CD8+ T Cells and Regulatory T Cells. PLoS ONE, 2008, 3, e3289.	2.5	48
247	Role of Vascular Leukocytes in Ovarian Cancer Neovascularization. , 2008, 622, 273-280.		11
248	Transcriptional Regulation of PIK3CA Oncogene by NF-ÎºB in Ovarian Cancer Microenvironment. PLoS ONE, 2008, 3, e1758.	2.5	41
249	Cancer Cell Lines as Genetic Models of Their Parent Histology: Analyses Based on Array Comparative Genomic Hybridization. Cancer Research, 2007, 67, 3594-3600.	0.9	65
250	Tumor Vascular Proteins As Biomarkers in Ovarian Cancer. Journal of Clinical Oncology, 2007, 25, 852-861.	1.6	172
251	Report on the ISBTC Mini-symposium on Biologic Effects of Targeted Therapeutics. Journal of Immunotherapy, 2007, 30, 577-590.	2.4	2
252	Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion. Cancer Research, 2007, 67, 1842-1852.	0.9	247

#	Article	IF	Citations
253	Integrative Genomic Analysis of Phosphatidylinositol 3â€²-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer. Clinical Cancer Research, 2007, 13, 5314-5321.	7.0	111
254	Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma. Cancer Research, 2007, 67, 8900-8905.	0.9	294
255	Monocytes TIE(2)d up in murky business. Blood, 2007, 109, 5076-5076.	1.4	2
256	Luteogenic Hormones Act through a Vascular Endothelial Growth Factor-Dependent Mechanism to Up-Regulate Î±5Î²1 and Î±vÎ²3 Integrins, Promoting the Migration and Survival of Human Luteinized Granulosa Cells. American Journal of Pathology, 2007, 170, 1561-1572.	3.8	19
257	miRNA genetic alterations in human cancers. Expert Opinion on Biological Therapy, 2007, 7, 1375-1386.	3.1	50
258	Immune Prognostic Factors in Ovarian Cancer: Lessons from Translational Research. Disease Markers, 2007, 23, 445-452.	1.3	5
259	Vascular Leukocytes: a Population with Angiogenic and Immunossuppressive Properties Highly Represented in Ovarian Cancer. , 2007, 590, 185-193.		20
260	Involvement of Endothelial CD44 during in Vivo Angiogenesis. American Journal of Pathology, 2006, 169, 325-336.	3.8	123
261	Manipulating T regulatory cells in cancer immunotherapy. Expert Review of Dermatology, 2006, 1, 589-597.	0.3	3
262	Laser-capture microdissection. Nature Protocols, 2006, 1, 586-603.	12.0	651
263	Prophylactic oophorectomy for ovarian cancer. Reviews in Gynaecological and Perinatal Practice, 2006, 6, 12-19.	0.3	0
264	Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer Biology and Therapy, 2006, 5, 635-642.	3.4	60
265	Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. Cancer Biology and Therapy, 2006, 5, 867-874.	3.4	20
266	MicroRNAs: A New Insight into Cancer Genome. Cell Cycle, 2006, 5, 2216-2219.	2.6	32
267	microRNAs exhibit high frequency genomic alterations in human cancer. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9136-9141.	7.1	977
268	Integrative Genomic Analysis of Protein Kinase C (PKC) Family Identifies PKCÎ¹ as a Biomarker and Potential Oncogene in Ovarian Carcinoma. Cancer Research, 2006, 66, 4627-4635.	0.9	118
269	Interferon Î² adenoviral gene therapy in a patient with ovarian cancer. Nature Clinical Practice Oncology, 2006, 3, 633-639.	4.3	29
270	Vascular leukocytes contribute to tumor vascularization. Blood, 2005, 105, 679-681.	1.4	183

#	Article	IF	Citations
271	The fibronectin receptor Î±5 integrin subunit is upregulated by cell-cell adhesion via a cyclic AMP-dependent mechanism: Implications for human trophoblast migration. American Journal of Obstetrics and Gynecology, 2005, 192, 1240-1253.	1.3	14
272	Oncolytic HSV Exerts Direct Antiangiogenic Activity in Ovarian Carcinoma. Human Gene Therapy, 2005, 16, 765-778.	2.7	81
273	HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Molecular Therapy, 2005, 12, 789-802.	8.2	119
274	T regulatory cell depletion can boost DC-based vaccines. Cancer Biology and Therapy, 2005, 4, 628-630.	3.4	4
275	Immunotherapy for gynaecological malignancies. Expert Opinion on Biological Therapy, 2005, 5, 1193-1210.	3.1	31
276	Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Research, 2005, 65, 925-32.	0.9	75
277	RNA interference, A potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer. Cancer Biology and Therapy, 2004, 3, 1283-1289.	3.4	18
278	Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine, 2004, 10, 942-949.	30.7	4,442
279	Tumor-infiltrating dendritic cell precursors recruited by a Î²-defensin contribute to vasculogenesis under the influence of Vegf-A. Nature Medicine, 2004, 10, 950-958.	30.7	431
280	Ovarian Carcinoma Expresses the NKG2D Ligand Letal and Promotes the Survival and Expansion of CD28â^' Antitumor T Cells. Cancer Research, 2004, 64, 2175-2182.	0.9	64
281	Signal pathway profiling of ovarian cancer from human tissue specimens using reverseâ€phase protein microarrays. Proteomics, 2003, 3, 2085-2090.	2.2	226
282	Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer. New England Journal of Medicine, 2003, 348, 203-213.	27.0	2,930
283	Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochemical and Biophysical Research Communications, 2003, 303, 1169-1178.	2.1	101
284	LETAL, A Tumor-Associated NKG2D Immunoreceptor Ligand, Induces Activation and Expansion of Effector Immune Cells. Cancer Biology and Therapy, 2003, 2, 446-451.	3.4	55
285	Intraperitoneal Oncolytic and Tumor Vaccination Therapy with Replication-Competent Recombinant Virus: The Herpes Paradigm. Current Gene Therapy, 2003, 3, 113-125.	2.0	12
286	BRCA1 and BRCA2 Mutations in Ovarian Carcinoma. , 2003, , 201-208.		0
287	Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clinical Cancer Research, 2003, 9, 264-72.	7.0	43
288	TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clinical Cancer Research, 2003, 9, 1517-27.	7.0	73

#	Article	IF	Citations
289	Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Research, 2003, 63, 3403-12.	0.9	204
290	The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Research, 2003, 63, 4225-31.	0.9	56
291	Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma. American Journal of Pathology, 2002, 161, 2295-2309.	3.8	129
292	Different Effects of Glucose Starvation on Expression and Stability of VEGF mRNA Isoforms in Murine Ovarian Cancer Cells. Biochemical and Biophysical Research Communications, 2002, 292, 860-868.	2.1	65
293	Replication-Selective Herpes Simplex Virus Type 1 Mutant Therapy of Cervical Cancer Is Enhanced by Low-Dose Radiation. Human Gene Therapy, 2002, 13, 627-639.	2.7	65
294	Prophylactic oophorectomy. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 597-609.	2.8	12
295	Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Therapy, 2000, 7, 275-283.	4.6	63
296	Prolonged Remission of Recurrent, Metastatic Placental Site Trophoblastic Tumor after Chemotherapy. Gynecologic Oncology, 2000, 76, 115-117.	1.4	26
297	Early ovarian cancer. Current Treatment Options in Oncology, 2000, 1, 129-137.	3.0	6
298	Regulated Expression and Potential Roles of p53 and Wilmsâ€™ Tumor Suppressor Gene (WT1) during Follicular Development in the Human Ovary1. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 449-459.	3.6	43
299	Follicular Atresia and Luteolysis Evidence of a Role for Nâ€Cadherin. Annals of the New York Academy of Sciences, 2000, 900, 46-55.	3.8	22
300	Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system. Annals of Thoracic Surgery, 1999, 68, 1756-1760.	1.3	17
301	N-Cadherin-Mediated Human Granulosa Cell Adhesion Prevents Apoptosis. American Journal of Pathology, 1999, 154, 1391-1406.	3.8	93
302	Chemotherapy resistance in ovarian cancer: New molecular perspectives. Obstetrics and Gynecology, 1998, 91, 783-792.	2.4	49
303	Macrophage-Colony Stimulating Factor (M-CSF) Regulates the Expression of Fibronectin and Its Î±5 Integrin Receptor in Human Trophoblasts*. Endocrinology, 1998, 139, 2190-2193.	2.8	21
304	CHEMOTHERAPY RESISTANCE IN OVARIAN CANCER. Obstetrics and Gynecology, 1998, 91, 783-792.	2.4	28
305	Differentiation-Dependent Expression of the BCL-2 Proto-Oncogene in the Human Trophoblast Lineage. Journal of the Society for Gynecologic Investigation, 1994, 1, 164-172.	1.7	66
306	Human Immunodeficiency Virus Type 1 Causes Productive Infection of Macrophages in Primary Placental Cell Cultures. Journal of Infectious Diseases, 1994, 169, 746-753.	4.0	70

#	Article	IF	Citations
307	Potential Roles for the Low Density Lipoprotein Receptor Family of Proteins in Implantation and Placentation. Annals of the New York Academy of Sciences, 1994, 734, 91-102.	3.8	7
308	Involvement of Placental Neurohormones in Human Parturition. Annals of the New York Academy of Sciences, 1991, 622, 331-340.	3.8	32
309	Doppler Velocimetry in Prolonged Pregnancy. Obstetrics and Gynecology, 1991, 77, 213-216.	2.4	30
310	Progestins Modulate the Action of Estrogen on Gonadotropin-Releasing Hormone, Luteinizing Hormone and Prolactin in the Rat. Gynecologic and Obstetric Investigation, 1990, 29, 197-202.	1.6	10
311	Cancer Gene Therapy: Targeted Genomedicines. , 0, , .		0